Living Rheum: Recent Episodes
ReachMD
Dedicated to uncovering clinical developments and treatment advancements in the field of rheumatology, Living Rheum delivers expert insights on patient management across a broad spectrum of rheumatic diseases, such as rheumatoid arthritis, lupus, scleroderma, osteoporosis, and more.
Guest: Martin Cheatle, PhD
A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Lupus arises from a complex interaction of genetics, environmental stimuli, and immune system errors. Dive into the pathophysiology behind the disease with Dr. Michelle Kahlenberg, the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and Professor of Internal Medicine and Dermatology at the University of Michigan, as she examines the mechanisms that contribute to the development of autoreactive immune responses. Dr. Kahlenberg also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Our approach to lupus management is accelerating, with emerging results on targeted therapies in skin and renal disease showing promise. Dr. Michelle Kahlenberg shares insights on emerging biologics, CAR-T innovations, and potential barriers in translating treatment breakthroughs into real-world patient care. Dr. Kahlenberg is the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and a Professor of Internal Medicine at Dermatology at the University of Michigan, and she spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Laura Cappelli, MD, MHS,MS
Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: John Bridges, MD, MS
For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Robin Dore, MD
Despite the challenges of managing rheumatoid arthritis—especially for patients with difficult-to-treat cases or a history of cancer—clinical trials, updated guidelines, and data-driven decision-making are helping to shape the future of care. Dive deeper into how rheumatoid arthritis treatment is evolving with Dr. Robin Dore, board-certified rheumatologist and Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Guest: Robin Dore, MD
Rheumatoid arthritis presents uniquely in every patient, which can make treatment decisions complex. As a result, it’s important to balance factors like symptom variations, patient concerns, and medical guidelines to find the right approach. Hear how risk-benefit discussions and evolving treatment strategies can shape care from Dr. Robin Dore, a board-certified rheumatologist and an Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Guest: Leonard H. Calabrese, DO
With at least 4 percent of patients who experience COVID-19 developing long COVID, improving care for post-infectious chronic conditions is critical. By prioritizing research and education on the rheumatological effects of acute infections, we can address these patients’ unmet needs. Join Dr. Leonard Calabrese, Vice Chairman of the Department of Rheumatic and Immunologic Disease and Head of Clinical Immunology at the Cleveland Clinic Foundation, as he explains what we know so far about these conditions.
Guest: Philip J. Mease, MD, MACR
Managing pain in chronic rheumatic conditions requires a comprehensive approach. Through education and innovative research, we can develop more effective ways to care for patients. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine, gives a preview into the future of pain management.
Guest: Philip J. Mease, MD, MACR
Chronic pain isn’t always caused by inflammation—in rheumatic conditions, nociplastic and neuropathic pain can both complicate treatment. Understanding these pain types is crucial to effective patient management. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center in Seattle and Clinical Professor at the University of Washington School of Medicine, explains the complexities behind each type of pain and key considerations for patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William F.C. Rigby, MD
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2403256 v1.0 - P
Expiration Date 04/16/2025
Guest: Jason Busse, PhD
In light of the opioid epidemic, the use of cannabis for therapeutic purposes is becoming of interest. But since there are other alternatives that are often more effective and have better safety profiles, it’s important to understand the evidence and guideline recommendations around these two treatment options. Here to share key considerations for using opioids and cannabis to treat patients living with chronic pain is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Guest: Jason Busse, PhD
Different clinical practice guidelines often have discrepancies from one another, making it a challenge for clinicians to determine which ones are more trustworthy. Here to break down the things clinicians should look for when sorting between guidelines that give discrepant recommendations is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Host: Michael Lewiecki, MD, FACP, FACE
Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tune in to hear Dr. Michael Lewiecki give us a recap of the session he presented at the 2024 Congress of Clinical Rheumatology.
Host: Michael Lewiecki, MD, FACP, FACE
Here to talk about current concepts in the management of osteoporosis like insurance coverage, therapy sequencing, and comparative effectiveness is Dr. Michael Lewiecki, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Stone, MD, MPH
Glucocorticoids are often successfully used as the mainstay of treatment for many inflammatory conditions, but adverse events associated with glucocorticoids use are common. Fortunately, there are steps we can take to reduce the risk of glucocorticoid toxicity, like monitoring patients, educating them on the possible side effects, and considering alternative treatments where available. Tune in to learn more about the side effects, risk factors, and prevention strategies with Dr. Charles Turck and Dr. John Stone.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.
MAT-US-2310647 v1.0 - P
Expiration Date 04/16/2025
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Appealing treatment options for patients with SpA might be right around the corner. So why do we need further imaging modalities and what do they have to offer? To give us a peek into the future, Dr. Ethan Craig is joined by Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
How can we overcome diagnostic challenges and improve awareness for Still’s disease? Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College to explore the diagnosis landscape for this disease.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Disease activity in patients with spondyloarthritis (SpA) may be challenging to assess. So when should ultrasound and MRI be used to support clinical assessment? To provide us with more insights into this topic, Dr. Ethan Craig is joined by Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
Joining Dr. Ethan Craig to explore the role of patient-reported outcomes and discuss possible obstacles in disease monitoring is Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Over the last 20 year or so, magnetic resonance imaging (MRI) has changed how we evaluate axial spondyloarthritis (axSpA). But with a concerning rate of false-positive MRIs in recent data, it’s time to review where the field stands now, and update what the role of MRI seems to be in the diagnosis of spondyloarthritis (SpA). Join Dr. Ethan Craig in this discussion with an expert in SpA imaging, Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
While Sjögren’s disease may be challenging to diagnose, imaging developments may improve the way we detect this disease.
To learn more, Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Diagnosing patients with peripheral spondyloarthritis (pSpA) can often be challenging, particularly when differentiating it from other causes of inflammatory and non-inflammatory arthritis. So what is the role of ultrasound when diagnosing pSpA in patients? Join Dr. Ethan Craig as he guides this discussion with Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 3/23
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Polygenic autoinflammatory diseases can present in several ways, such as in still’s disease and systemic juvenile idiopathic arthritis. To share key insights on these diseases, Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
From therapeutic options to potential outcomes, what factors should we consider when escalating treatment for patients with axial spondyloarthritis? Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center to dive into these key considerations.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Sjogren's disease can be challenging to diagnose given that it can manifest in several different ways. How can we overcome this obstacle?
To share insights on combating diagnostic challenges, Dr. Ethan Craig is joined by Dr. Sara McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What do we need to know about providing infusion medication therapies to patients with rheumatologic diseases, and how should we talk to our patients about this treatment option? Joining Dr. Jason Liebowitz to explore rheumatology infusion therapy are Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To figure out how to improve the detection of fibromyalgia and axial spondyloarthritis, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Because Sjogren's disease has no calculable disease activity scores or established guidelines, how do clinicians monitor disease activity?
Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin to discuss activity monitoring for Sjögren’s disease.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Different domains of psoriatic arthritis can look different in each of our patients. How should that factor into our evaluation and treatment approach for this disease? Dr. Jason Liebowitz sits down with Dr. Laura Coates, an Associate Professor at Oxford University, to explore a domain-based approach to care.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What are some ways we can incorporate shared decision-making into the treatment of rheumatologic diseases? To answer that question, Dr. Jason Liebowitz joins Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To help us understand how axial spondyloarthritis (axSpA) and inflammatory back pain (IBP) differ, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
249165 11/22
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Given that recommendations for treatment are constantly evolving, how should we adjust our therapeutic approach to provide optimal care? To answer that question, Dr. Jason Liebowitz is joined by Dr. Laura Coates, an Associate Professor at Oxford University.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
245473 11/22
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Treatment for monogenic autoinflammatory disease can look different for our pediatric patients and our adult patients. What do we need to know? Dr. Jason Liebowitz sits down with Dr. Bella Mehta from Cornell Medical College to discuss treating these diseases.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
With biologic therapies emerging over the past two decades, what do we need to know about them? Dr. Jason Liebowitz is joined by Dr. Jonathan Greer and Ms. Karen McKerihan to share their perspectives on these new biologics.
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
As advancements in imaging continue to emerge, what does that mean for the management of gout, calcium pyrophosphate deposition, and crystalline arthritis? To answer this question, Dr. Jason Liebowitz is joined by Dr. Sara Tedsechi from Harvard Medical School.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
So how and when should we escalate or change treatments in patients with psoriatic arthritis (PsA)? To answer this question, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants
10/22 236268
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
For patients with oligoarticular arthritis, how can imaging features help us distinguish psoriatic arthritis from other inflammatory processes? Joining Dr. Ethan Craig to answer that question is Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie-Beatty, MD, MSCE
How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The risk of developing cancer may be higher in patients with spondyloarthritis, or SpA for short.1-6 What do we need to know about the risk of cancer, as well as other malignancies in these patients? Dr. Anisha Dua joins Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to explore malignancies in SpA.
Dr. Dua and Dr. Husni are Novartis consultants.
- Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:1-6.
- Gross R, Schwartzman-Morris J, Krathen M, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481.
- Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatology. 2016;152(3):282-290.
- Moon H-I, Chang H-J, Kim J-E, Ko H-Y, Ann S-H, Min C-K. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009;44(3):182-187.
- Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322.
- Karmacharya P, Shahukhal …
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
With several guidelines available—what imaging considerations should we keep in mind when it comes to diagnosing giant cell arthritis (GCA)? Joining Dr. Anisha Dua to walk us through the guidelines and make recommendations is Dr. Mike Putman.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The estimates of prevalence of depression across the axial spondyloarthritis spectrum ranges from 11% to 64%. How we can help these patients manage their mental health? To find out more, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
Zhao SS, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):1-9.
196466 6/22
Host: Monica Schwartzman, MD, MS
Guest: Joerg Ermann, MD
Axial spondyloarthritis is a chronic inflammatory rheumatic disease that affects the axial skeleton causing severe pain, stiffness, and fatigue. Fortunately, advances in its management have vastly improved symptoms and quality of life for our patients. So what exactly are the developments that have been made in the treatment of this disease? Tune in as Dr. Monica Schwartzman is joined by Dr. Joerg Ermann to discuss the recent therapeutic advances in axial spondyloarthritis.
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some ways we can better recognize the clinical features of giant cell arteritis (GCA)? Dr. Anisha Dua is joined by Dr. Mike Putman from the Medical College of Wisconsin to share detection and diagnosis strategies.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve diversity in the rheumatology workforce? Joining Dr. Anisha Dua to explore underrepresentation in the workforce are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Guest: Elaine Husni, MD, MPH
Host: Anisha Dua, MD, MPH
Physical activity has shown to have many benefits for patients with spondyloarthritis, or SpA for short. What kind of role does it have in the treatment of these patients? To answer this question, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Dr. Dua and Dr. Husni are Novartis consultants.
O’Dwyer T, O’Shea F, Wilson F. Physical activity in spondyloarthritis: a systematic review. Rheumatol Int. 2015;35(3):393-404.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some of the social determinants that can impact patient outcomes? Joining Dr. Anisha Dua to share strategies to improve these inequities are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Shared treatment decisions can help guide patient care—but how can we implement them in our practice? Drs. Jason Liebowitz and Michael Putman share tips and strategies to implement shared decision-making (SDM) in rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
Patients with spondyloarthritis, or SpA for short, can be at an increased cardiovascular risk.1,2 To learn how we can better understand and manage this risk, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
- Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatol (United Kingdom). 2020;59:iv47-iv57.
- Papagoras C, Markatseli TE, Saougou I, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2014;81(1):57-63.
196466 6/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Social media is often used as a tool to network and connect to people around the world—but can rheumatologists use it to connect with their patients? Drs. Jason Liebowitz and Michael Putman share how rheumatologists can use it to improve care.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some ways we can improve diversity in our workforce? Joining Dr. Anisha Dua to share how clinicians can make the workforce more inclusive are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
As evidence-based medicine (EBM) continues to evolve, what do rheumatologists need to know to keep up? Drs. Jason Liebowitz and Michael Putman dive into EBM and its role in the field of rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve representation in rheumatology clinical trials? To share strategies, Dr. Anisha Dua joins Dr. Grace Wright and Dr. Irene Blanco to discuss diversity in clinical trials.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
What do we need to know about the latest technologies changing the field of rheumatology? Drs. Jason Liebowitz and Michael Putman share the latest innovations.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
192544 4/22
Host: Jennifer Caudle, DO
Guest: David S. Batt, MD
Many factors can lead to diagnostic delays when it comes to systemic lupus erythematosus (SLE), such as the wide range of clinical manifestations and the variable age of onset. So given those factors, how can we get better at recognizing SLE early on to help close the diagnostic gap? And then once we do diagnose patients, what strategies can we use to tighten the therapeutic window? Joining Dr. Jennifer Caudle to answer those and other key questions regarding early intervention strategies for SLE is Dr. David Batt.
Host: Jacob Sands, MD
Guest: Daniel G. Arkfeld, MD
The focus of lupus treatment has evolved from controlling symptoms to taking a treat-to-target approach to help patients feel more comfortable and to prevent organ damage. So what role do biologics play in all of this? Find out with Dr. Jacob Sands as he speaks with Dr. Daniel Arkfeld, who shares key insights on this approach to treating lupus.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Guest: Robin Dore, MD
When managing patients with lupus nephritis, it’s imperative that rheumatologists and nephrologists work together to coordinate care. Unfortunately, several challenges can keep us from putting care coordination strategies into practice, so how can we overcome those challenges and incorporate shared decision-making into our clinical approach to lupus nephritis? Joining Dr. Charles Turck to share their perspectives are rheumatologist Dr. Robin Dore and nephrologist Dr. Gates Colbert.